Full Press Release Details
Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to
at the Third International Conference on Advanced
and Treatments for Diabetes in Basel, Switzerland
Israel - February 10, 2010- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB)
(www.oramed.com), a developer of alternative drug delivery systems, announced
today that its Chief Scientific Officer, Miriam Kidron, Ph.D., was chosen to
lecture at the Third International Conference on Advanced Technologies and
Treatments for Diabetes (ATTD) to take place in Basel, Switzerland on February
11, 2010. Dr. Kidron will present the following abstract in Hall B at
3:15 pm: "Assessment of Oral Insulin Formulations in the Healthy Male Volunteers
- Safety and Pharmacodynamic Comparisons".
the conference website, the conference "presents professionals with cutting-edge
technologies from entrepreneurs racing to develop effective and advanced devices
and systems for the treatment and prevention of diabetes and related
illnesses." For more information please visit the conference website at:
currently conducting a Phase 2B clinical trial in South Africa on its flagship
product an oral insulin capsule. Results are expected at the end of the first
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed's technology is based on over 25 years of
research by top research scientists at Jerusalem's Hadassah Medical Center.
Oramed's corporate and R&D headquarters are based in Jerusalem.
information, please visit www.oramed.com.
Some of the statements contained in
this press release are forward-looking statements which involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Oramed, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from other
pharmaceutical or biotechnology companies; and Oramed's ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to Oramed's filings with the
Securities and Exchange Commission for a comprehensive list of risk factors that
could cause actual results, performance or achievements of Oramed to differ
materially from those expressed or implied in such forward looking statements.
Oramed undertakes no obligation to update or revise any forward-looking
and Investor Relations Contact:
Pharmaceuticals Inc.
Email: tara@oramed.com